证券代码：600436 证券简称：片仔癀 公告编号：2025-022 漳州片仔癀药业股份有限公司 重要内容提示： 拟投资标的名称：漳州高鑫润信大健康产业投资合伙企业（有 限合伙）（暂定名，以工商注册为准；以下简称"高鑫润信基金"）。 拟投资领域：本基金的主要投资领域为医疗健康领域，包含药 品、医疗器械、医疗健康上游供应链及零部件、食品保健品、合成生 物、化工材料、消费医疗等大健康相关领域，医疗健康以外的其他领 域投资占比不超过本基金认缴出资规模的 10%。 拟投资金额：漳州片仔癀药业股份有限公司（以下简称"公司"） 全资子公司漳州片仔癀投资管理有限公司（以下简称"片仔癀投资"） 拟作为有限合伙人以自有或自筹资金认缴出资人民币 20,000 万元， 占高鑫润信基金目标募集规模的比例为 20%。 本次对外投资系与关联方漳州片仔癀资产经营有限公司（以下 简称"资产经营"）、漳州市旅游投资集团有限公司（以下简称"旅 投集团"）共同投资，构成关联交易，但未构成《上市公司重大资产 重组管理办法》规定的重大资产重组。 1 关于投资参与高鑫润信基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...

1 / 2 金暨关联交易的公告》（2025-022 号）。 本议案无需提交至公司股东大会审议。 证券代码：600436 证券简称：片仔癀 公告编号：2025-023 漳州片仔癀药业股份有限公司 第七届监事会第二十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届监事 会第二十二次会议于 2025 年 8 月 6 日（星期三）上午 11：00 在公司 片仔癀大厦 21 楼会议室以通讯会议方式召开。会议通知和议案以专 人送达、电子邮件方式发出。本次会议应参加表决的监事 5 名，实际 表决的监事 5 名。会议召开符合《公司法》和《漳州片仔癀药业股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，合法、 有效。本次会议由监事会主席许式彬先生主持，议案经与会监事审议， 做出如下决议： 一、审议通过《公司关于全资子公司与专业投资机构共同投资设 立高鑫润信基金暨关联交易的议案》； 监事会认为：公司本次与中信建投资本管理有限公司共同投资高 鑫润信基金暨关联交易事项符合 ...

Group 1 - The core viewpoint of the article is that the company Pianzaihuang (600436.SH) is actively seeking new growth points by investing in the healthcare industry, specifically through the establishment of the GaoXinRunXin Fund with a target fundraising scale of 1 billion yuan [1] - The company’s wholly-owned subsidiary, Pianzaihuang Investment, plans to contribute 200 million yuan, which represents 20% of the fund's target size [1] - The GaoXinRunXin Fund will primarily invest in the healthcare sector, including pharmaceuticals, medical devices, upstream supply chains, health food, synthetic biology, chemical materials, and consumer healthcare, with investments outside the healthcare sector not exceeding 10% of the fund's total contributions [1]

Group 1 - The company Pianzaihuang (600436.SH) announced that its wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., plans to invest 200 million RMB as a limited partner, accounting for 20% of the target fundraising scale of the Gaoxin Runxin Fund [1] - The main investment areas of the fund include the healthcare sector, covering pharmaceuticals, medical devices, upstream supply chains and components, health food, synthetic biology, chemical materials, and consumer healthcare, with investments outside the healthcare sector not exceeding 10% of the fund's subscribed capital [1]

Core Viewpoint - The company Pianzaihuang (600436) announced an investment in the health industry by participating in the GaoXinRunXin Fund, which aims to raise a total of 1 billion yuan [1] Group 1: Investment Details - The GaoXinRunXin Fund has a target fundraising scale of 1 billion yuan [1] - Pianzaihuang's wholly-owned subsidiary plans to invest 200 million yuan, representing 20% of the fund's target size [1]

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of Pian Zai Huang Investment plans to invest 200 million RMB as a limited partner in the Gao Xin Run Xin Fund, which targets a total fundraising scale of 1 billion RMB, representing 20% of the fund's goal [1] Group 1: Investment Details - The Gao Xin Run Xin Fund primarily focuses on the healthcare sector, including pharmaceuticals, medical devices, upstream supply chains, health food products, synthetic biology, chemical materials, and consumer healthcare [1] - Investments outside the healthcare sector will not exceed 10% of the total committed capital of the fund [1] Group 2: Transaction Classification - This investment constitutes a related party transaction but does not qualify as a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies" [1]

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Core Viewpoint - The stock price of Pian Zai Huang is currently 202.01 yuan, reflecting a 0.64% increase from the previous trading day, with a trading volume of 571 million yuan [1] Company Overview - Pian Zai Huang is a well-established Chinese medicine manufacturer, primarily engaged in the production of traditional Chinese medicine, including products like Pian Zai Huang and An Gong Niu Huang Wan [1] - The company is recognized as a time-honored brand in the pharmaceutical industry [1] Recent Developments - The National Health Commission and the National Administration of Traditional Chinese Medicine recently released a treatment plan for Chikungunya fever, which includes An Gong Niu Huang Wan as a recommended medication [1] - An Gong Niu Huang Wan is produced using traditional methods and has previously been included in the treatment guidelines for dengue fever [1] Financial Performance - On August 4, the net inflow of main funds into Pian Zai Huang reached 57.05 million yuan, with a total net inflow of 106 million yuan over the past five days [1]

金融界消息 截至2025年8月4日收盘，片仔癀（600436）报收于202.01元，上涨0.64%，换手率0.47%， 成交量2.83万手，成交金额5.71亿元。 资金流向方面，今日主力资金净流入5705.43万元，占比成交额9.99%。其中，超大单净流入3055.08万 元、占成交额5.35%，大单净流入2650.35万元、占成交额4.64%，中单净流出流出1724.36万元、占成交 额3.02%，小单净流出3981.07万元、占成交额6.97%。 片仔癀最新一期业绩显示，截至2025一季报，公司营业总收入31.42亿元、同比减少0.92%，归属净利润 10.00亿元，同比增长2.59%，扣非净利润10.05亿元，同比增长1.69%，流动比率5.240、速动比率 3.112、资产负债率14.29%。 来源：金融界 天眼查商业履历信息显示，漳州片仔癀药业股份有限公司，成立于1999年，位于漳州市，是一家以从事 医药制造业为主的企业。企业注册资本60331.721万人民币，实缴资本60331.72万人民币。公司法定代表 人为林志辉。 通过天眼查大数据分析，漳州片仔癀药业股份有限公司共对外投资了27家企业，参与招 ...

Group 1 - The recent outbreak of Chikungunya fever in certain southern cities of China has led to local transmission, prompting the issuance of the 2025 version of the Chikungunya fever diagnosis and treatment plan by the National Health Commission and the National Administration of Traditional Chinese Medicine [1] - The treatment plan emphasizes that Chikungunya fever is primarily transmitted through bites from Aedes mosquitoes carrying the virus, and there is currently no specific treatment available, focusing instead on symptomatic supportive care [1] - The plan also highlights the role of traditional Chinese medicine in treating Chikungunya fever, categorizing it under the "damp-heat" syndrome, with specific treatment methods outlined for the acute phase [1] Group 2 - Pianzaihuang Pharmaceutical Co., Ltd. is noted for its production of traditional Chinese medicine, including the well-known "An Gong Niu Huang Wan," which is made from selected authentic medicinal materials and adheres to traditional manufacturing processes [1] - The company has a long history and is recognized as a time-honored brand in China, producing over 20 varieties of traditional Chinese medicine, including Pianzaihuang and An Gong Niu Huang Wan [1] - Pianzaihuang was previously included in the 2014 Dengue fever treatment guidelines, indicating its established role in the treatment of viral infections [1]